Expectant management noninferior to early ibuprofen treatment for patent ductus arteriosus

Written By :  Dr.Niharika Harsha B
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-15 14:30 GMT   |   Update On 2022-12-15 14:30 GMT
Advertisement

A new study found that with regards to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age in extremely premature infants, expectant management for patent ductus arteriosus (PDA) was not less than early ibuprofen treatment. The study results were published in The New England Journal of Medicine.  

Patent ductus arteriosus is common in premature infants and its management is still arguable. Cyclooxygenase inhibitors are frequently prescribed to infants with patent ductus arteriosus (PDA), but their efficacy is unknown. Due to the limited evidence, researchers from Netherlands and Belgium conducted a study to assess whether expectant management would be non-inferior to early ibuprofen treatment concerning necrotizing enterocolitis, moderate-to-severe bronchopulmonary dysplasia, or death as assessed at a postmenstrual age of 36 weeks. 

A multicenter, noninferiority trial, was carried out by randomly assigning infants with echocardiographically confirmed PDA (diameter, >1.5 mm, with left-to-right shunting) who were extremely preterm (<28 weeks gestational age) to receive either expectant management or early ibuprofen treatment. The composite primary outcome included necrotizing enterocolitis (Bell's stage IIa or higher), moderate to severe bronchopulmonary dysplasia, or death at 36 weeks postmenstrual age. The non-inferiority of expectant management as compared with early ibuprofen treatment was defined as an absolute risk difference with an upper boundary of the one-sided 95% confidence interval of less than 10 percentage points. 

RESULTS: 

  • A total of 273 infants underwent randomization.
  • The median gestational age was 26 weeks, and the median birth weight was 845 g.
  • A primary-outcome event occurred in 63 of 136 infants (46.3%) in the expectant-management group and 87 of 137 (63.5%) in the early-ibuprofen group (P<0.001 for noninferiority).
  • Necrotizing enterocolitis occurred in 24 of 136 infants in the expectant-management group and 21 of 137 in the early-ibuprofen group; bronchopulmonary dysplasia occurred in 39 of 117 infants and 57 of 112, respectively.
  • The death occurred in 19 of 136 infants (14.0%) and 25 of 137 (18.2%), respectively (absolute risk difference, −4.3 percentage points; two-sided 95% CI, −13.0 to 4.4). 
outcomes 

expectant-management group, 

early-ibuprofen group, 

absolute risk difference

95% confidence interval [CI]

primary-outcome event 

63 (46.3%) n=136

87 (63.5%) n=137

 −17.2 percentage points

−7.4

Necrotizing enterocolitis 

24 (17.6%) n=136

21 (15.3%) n=137

2.3 percentage points

−6.5 to 11.1 

bronchopulmonary dysplasia 

39 (33.3%) n=117

57 (50.9%) n=112

 −17.6 percentage points

−30.2 to −5.0

  • Rates of other adverse outcomes were similar in the two groups. 

Thus, the trial showed that expectant management for PDA in extremely premature infants was non-inferior to early ibuprofen treatment. 

Further reading: Hundscheid T, Onland W, Kooi EMW, et al. Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus [published online ahead of print, 2022 Dec 6]. N Engl J Med. 2022;10.1056/NEJMoa2207418. doi:10.1056/NEJMoa2207418

Tags:    
Article Source : The New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News